XML 63 R43.htm IDEA: XBRL DOCUMENT
v3.20.4

Quarterly Financial Information (Unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract] |
Schedule of quarterly financial information (unaudited) | The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2020 and 2019 (unaudited):
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2020 |  | September 30, 2020 |  | June 30, 2020 |  | March 31, 2020
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenues: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 5,003,494 |  |  | $ | 21,490 |  |  | $ | 74,102 |  |  | $ | 71,500 |
Revenue under collaborative research and development arrangements from affiliated entities | 82,774 |  |  | 103,684 |  |  | 95,146 |  |  | 1,172,126 |
Other revenue, including from affiliated entities | 494,313 |  |  | 111,004 |  |  | 97,939 |  |  | 83,648 |
Total revenues | 5,580,581 |  |  | 236,178 |  |  | 267,187 |  |  | 1,327,274 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 26,302,561 |  |  | 26,455,112 |  |  | 22,376,575 |  |  | 19,111,188 |
General and administrative | 8,617,458 |  |  | 10,110,506 |  |  | 11,071,510 |  |  | 7,448,354 |
Total operating expenses | 34,920,019 |  |  | 36,565,618 |  |  | 33,448,085 |  |  | 26,559,542 |
Loss from operations | (29,339,438) |  |  | (36,329,440) |  |  | (33,180,898) |  |  | (25,232,268) |
Interest income | 931,168 |  |  | 896,710 |  |  | 1,067,399 |  |  | 416,569 |
Interest expense | (1,068,008) |  |  | (1,984,046) |  |  | (2,846,641) |  |  | (2,803,755) |
Change in fair value of derivative liability | — |  |  | 35,306,000 |  |  | (97,755,000) |  |  | (13,221,977) |
Gain (loss) on investment in affiliated entities | 306,317 |  |  | 26,951,898 |  |  | (3,883,176) |  |  | 13,181,619 |
Net unrealized gain on available-for-sale equity securities | 1,070,975 |  |  | 1,315,980 |  |  | 4,358,634 |  |  | (5,050,092) |
Other income (expense), net | 9,350 |  |  | (136,644) |  |  | (152,102) |  |  | (425,500) |
Gain on deconsolidation of Geneos | — |  |  | — |  |  | 4,121,075 |  |  | — |
Loss on extinguishment of convertible bonds | — |  |  | (8,177,043) |  |  | — |  |  | — |
Gain on extinguishment of convertible senior notes | 5,674,435 |  |  | 3,087,595 |  |  | — |  |  | — |
Net income (loss) before income tax benefit and share in net loss of Geneos | $ | (22,415,201) |  |  | $ | 20,931,010 |  |  | $ | (128,270,709) |  |  | $ | (33,135,404) |
Share in net loss of Geneos | (1,923,179) |  |  | (1,759,674) |  |  | (901,757) |  |  | — |
Net income (loss) | $ | (24,338,380) |  |  | $ | 19,171,336 |  |  | $ | (129,172,466) |  |  | $ | (33,135,404) |
Net loss attributable to non-controlling interest | — |  |  | — |  |  | 469,407 |  |  | 594,350 |
Net income (loss) attributable to Inovio Pharmaceuticals, Inc. | $ | (24,338,380) |  |  | $ | 19,171,336 |  |  | $ | (128,703,059) |  |  | $ | (32,541,054) |
Net income (loss) per share |  |  |  |  |  |  |
Basic | $ | (0.14) |  |  | $ | 0.12 |  |  | $ | (0.83) |  |  | $ | (0.26) |
Diluted | $ | (0.14) |  |  | $ | 0.11 |  |  | $ | (0.83) |  |  | $ | (0.26) |
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2019 |  | September 30, 2019 |  | June 30, 2019 |  | March 31, 2019
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenues: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 184,523 |  |  | $ | 617,427 |  |  | $ | 64,283 |  |  | $ | 2,770,712 |
Revenue under collaborative research and development arrangements from affiliated entities | 55,665 |  |  | 53,014 |  |  | 71,390 |  |  | 55,579 |
Other revenue, including from affiliated entities | 39,300 |  |  | 196,422 |  |  | — |  |  | 3,614 |
Total revenues | 279,488 |  |  | 866,863 |  |  | 135,673 |  |  | 2,829,905 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 22,003,955 |  |  | 19,137,209 |  |  | 22,486,266 |  |  | 24,389,888 |
General and administrative | 8,696,586 |  |  | 5,681,441 |  |  | 5,850,101 |  |  | 6,975,029 |
Total operating expenses | 30,700,541 |  |  | 24,818,650 |  |  | 28,336,367 |  |  | 31,364,917 |
Loss from operations | (30,421,053) |  |  | (23,951,787) |  |  | (28,200,694) |  |  | (28,535,012) |
Interest income | 587,679 |  |  | 637,438 |  |  | 755,330 |  |  | 625,535 |
Interest expense | (2,668,837) |  |  | (2,428,671) |  |  | (2,194,783) |  |  | (656,248) |
Change in fair value of derivative liability | (4,315,105) |  |  | 2,551,453 |  |  | — |  |  | — |
Loss from investment in affiliated entities | (1,681,401) |  |  | (485,841) |  |  | (173,212) |  |  | (750,103) |
Other income (expense), net | 263,571 |  |  | 140,956 |  |  | 127,512 |  |  | (35,839) |
Net loss before income tax benefit | (38,235,146) |  |  | (23,536,452) |  |  | (29,685,847) |  |  | (29,351,667) |
Income tax benefit | 87,764 |  |  | — |  |  | 106,771 |  |  | 62,800 |
Net loss | (38,147,382) |  |  | (23,536,452) |  |  | (29,579,076) |  |  | (29,288,867) |
Net loss attributable to non-controlling interest | 485,344 |  |  | 445,759 |  |  | 191,850 |  |  | 69,605 |
Net loss attributable to Inovio Pharmaceuticals, Inc. | $ | (37,662,038) |  |  | $ | (23,090,693) |  |  | $ | (29,387,226) |  |  | $ | (29,219,262) |
Net loss per share |  |  |  |  |  |  |
Basic | $ | (0.38) |  |  | $ | (0.23) |  |  | $ | (0.30) |  |  | $ | (0.30) |
Diluted | $ | (0.38) |  |  | $ | (0.25) |  |  | $ | (0.30) |  |  | $ | (0.30) |

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration